Is Clorox (CLX) a risky stock?
As of July 21, 2026, Clavix grades Clorox (CLX) C- for risk, a composite score of 53 out of 100 on an A+ to F scale, which puts CLX in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind CLX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CLX scores on each, as of July 21, 2026.
What's moving CLX's risk right now
Company-specific signals Clavix flags behind CLX's current grade, drawn from recent news and filings as of July 21, 2026.
Clorox lowered its 2026 guidance and is dealing with rising costs that could squeeze near-term profits. The upcoming fourth-quarter results are a key catalyst, if the company falls short of its revised outlook, the stock could face more pressure.
JPMorgan cut its Clorox price target to $92, saying the stock is likely to trail its benchmark. The cut signals reduced confidence in the near-term outlook and points to further downside from current levels.
UBS raised its Clorox price target to $100, a modest bump. But the firm kept a neutral rating, saying the stock is roughly fairly valued with limited near-term upside.
What a C- grade means
On the Clavix A+ to F scale, CLX's composite of 53 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CLX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.